In general the disease is characterised by non-specific symptoms between the ages of 5 and 30 years
The sponsor described the safety profile as comparable with the broader GLP-1 receptor agonist class
Common community options include adding cagrilintide for satiety, adding MOTS-c for mitochondrial support, or adding a GH secretagogue (covered in the Advanced Recomp Stack) for lean mass
Would another therapy be more appropriate
GLP-1s work by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity in ways that compound over months of consistent use
In controlled laboratory settings, Epithalon is primarily studied for its interactions with telomerase activity, DNA stability, and cellular ageing pathways